Table 1 Descriptive Statistics.

From: The Association between Cannabis Product Characteristics and Symptom Relief

  Mean Std. Dev. Minimum Maximum
Panel A: Product Type (19,910 sessions, 3,341 users)
Concentrate 0.17 0.38 0 1
Edible 0.05 0.21 0 1
Flower 0.74 0.44 0 1
Tincture 0.04 0.20 0 1
Topical 0.00 0.06 0 1
Panel B: Subspecies (17,197 sessions, 2,996 users)
Hybrid 0.48 0.50 0 1
C. indica 0.30 0.46 0 1
C. sativa 0.22 0.41 0 1
Panel C: Combustion Method (16,902 sessions, 2,936)
Joint 0.13 0.33 0 1
Pipe 0.43 0.49 0 1
Vape 0.45 0.50 0 1
Panel D: THC (6,958 sessions, 1,260 users)
% THC 28.3 22.8 0 100
THC < 10% 0.16 0.36 0 1
THC 10–19% 0.29 0.45 0 1
THC 20–34% 0.36 0.48 0 1
THC 35%+ 0.20 0.40 0 1
Panel E: CBD (5,400 sessions, 1,123 users)
% CBD 11.6 16.0 0 100
CBD < 1% 0.25 0.43 0 1
CBD 1–9% 0.33 0.47 0 1
CBD 10–34% 0.34 0.47 0 1
CBD 35%+ 0.08 0.28 0 1
Panel F: Outcome and Control Variables (19,910 sessions, 3,341 users)
Symptom Change −3.5 2.6 −10 9
Starting Symptom Level 6.0 2.2 1 10
Ending Symptom Level 2.4 2.2 0 10
Panel G: Side Effects (15,617 sessions, 2,757 users)
Any Negative Side Effect 0.62 0.48 0.00 1.00
% of Negative Side Effects 0.12 0.14 0.00 0.92
Any Positive Side Effect 0.95 0.23 0.00 1.00
% of Positive Side Effects 0.25 0.18 0.00 1.00
Any Context-Specific Side Effect 0.78 0.41 0.00 1.00
% of Context-Specific Side Effects 0.22 0.20 0.00 1.00
  1. Notes: Nineteen positive, twelve negative, and eleven context-specific side effects were available for selection.